Rationale Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Objectives Here, we report on safety and efficacy
Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind,
Background Psilocybin is being studied for use in treatment-resistant depression. Methods In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression
Abstract Salvinorin A is a potent, selective nonnitrogenous kappa opioid agonist and the known psychoactive constituent of Salvia divinorum, a member of the mint family
Background Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about
Abstract Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To
Abstract Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated
©2025 Unlimited Sciences. All rights reserved.
We hate pop-ups as much as you do, but if you want to stay up to date about the latest news in the psychedelic space and learn about our ground-breaking psychedelic research, please consider signing up for our newsletter below.